Progress in antisense technology
- PMID: 14746510
- DOI: 10.1146/annurev.med.55.091902.104408
Progress in antisense technology
Abstract
Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.
Similar articles
-
Antisense strategies.Curr Mol Med. 2004 Aug;4(5):465-87. doi: 10.2174/1566524043360375. Curr Mol Med. 2004. PMID: 15267220 Review.
-
RNAi: a novel antisense technology and its therapeutic potential.Med Sci Monit. 2006 Apr;12(4):RA67-74. Epub 2006 Mar 28. Med Sci Monit. 2006. PMID: 16572063 Review.
-
Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.Curr Opin Mol Ther. 2001 Jun;3(3):239-43. Curr Opin Mol Ther. 2001. PMID: 11497347 Review.
-
Application of antisense oligonucleotides for gene functionalization and target validation.Curr Opin Mol Ther. 1999 Jun;1(3):359-71. Curr Opin Mol Ther. 1999. PMID: 11713801 Review.
-
Antisense oligonucleotides as therapeutics for malignant diseases.Semin Oncol. 1997 Apr;24(2):187-202. Semin Oncol. 1997. PMID: 9129689 Review.
Cited by
-
Stability and free energy calculation of LNA modified quadruplex: a molecular dynamics study.J Comput Aided Mol Des. 2012 Mar;26(3):289-99. doi: 10.1007/s10822-012-9548-z. Epub 2012 Mar 29. J Comput Aided Mol Des. 2012. PMID: 22456858
-
Nano-flares for mRNA regulation and detection.ACS Nano. 2009 Aug 25;3(8):2147-52. doi: 10.1021/nn9003814. ACS Nano. 2009. PMID: 19702321 Free PMC article.
-
Chemistry, structure and function of approved oligonucleotide therapeutics.Nucleic Acids Res. 2023 Apr 11;51(6):2529-2573. doi: 10.1093/nar/gkad067. Nucleic Acids Res. 2023. PMID: 36881759 Free PMC article. Review.
-
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.Respir Res. 2009 May 20;10(1):39. doi: 10.1186/1465-9921-10-39. Respir Res. 2009. PMID: 19457265 Free PMC article.
-
Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.Mediators Inflamm. 2014;2014:353614. doi: 10.1155/2014/353614. Epub 2014 Apr 2. Mediators Inflamm. 2014. PMID: 24803739 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
